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Abstract
Background: Despite the extensive use of efficacious vaccines, pertussis still ranks among the major causes of childhood
mortality worldwide. Two types of pertussis vaccines are currently available, whole-cell, and the more recent acellular
vaccines. Because of reduced reactogenicity and comparable efficacy acellular vaccines progressively replace whole-cell
vaccines. However, both types require repeated administrations for optimal efficacy. We have recently developed a live
attenuated vaccine candidate, named BPZE1, able to protect infant mice after a single nasal administration.
Methodology/Principal Findings: We determined the protective mechanism of BPZE1-mediated immunity by using passive
transfer of T cells and antibodies from BPZE1-immunized mice to SCID mice. Clearance of Bordetella pertussis from the lungs
was mediated by both BPZE1-induced antibodies and CD4
+, but not by CD8
+ T cells. The protective CD4
+ T cells comprised
IFN-c-producing and IL-17-producing subsets, indicating that BPZE1 induces both Th1 and Th17 CD4
+ T cells. In addition,
and in contrast to acellular pertussis vaccines, BPZE1 also cross-protected against Bordetella parapertussis infection, but in
this case only the transfer of CD4
+ T cells conferred protection. Serum from BPZE1-immunized mice was not able to kill B.
parapertussis and did not protect SCID mice against B. parapertussis infection.
Conclusions/Significance: The novel live attenuated pertussis vaccine BPZE1 protects in a pre-clinical mouse model against
B. pertussis challenge by both BPZE1-induced antibodies and CD4
+ T cell responses. It also protects against B. parapertussis
infection. However, in this case protection is only T cell mediated.
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Introduction
Bordetella pertussis is the main etiological agent of whooping
cough or pertussis, an acute respiratory disease with increasing
prevalence and incidence, particularly in neonates [1,2]. Despite
the extensive use of efficacious vaccines, B. pertussis still represents a
major global public health problem and one of the top 10 causes of
childhood mortality [3–5]. Two types of pertussis vaccines are
currently available [6]. The first generation vaccines consist of
killed whole B. pertussis cells (wcPV) and have shown up to over
90% protective efficacy [7]. However, these vaccines have been
associated with local and systemic side-effects, including local
swelling, high fever and, in rare cases, encephalopathy and even
death. These drawbacks have led to the development of new-
generation, acellular vaccines (aPV). Initially developed and used
in Japan, they consist of highly purified protective antigens [8–10].
Although the aPV have been shown to be much less reactogenic
than the wcPV, three vaccine injections are still needed for optimal
protection, and the protective efficacy of the best aPV has
consistently been lower than that of the best wcPV [6,11].
Furthermore, the production of aPV is much more expensive than
that of wcPV, making them less affordable for developing
countries. None of the currently available vaccines targets mucosal
immunity, although B. pertussis is a mucosal pathogen, and the
infection strictly confined to the upper respiratory tract. Mucosal
immunity could therefore conceivably contribute to protection
[12].
In addition to B. pertussis, Bordetella parapertussis, a closely related
species sharing many of the B. pertussis virulence factors, can also
cause a whooping cough-like disease. Both pathogens can be found
in the same infected host at the same time [13,14]. Reported
frequencies of whooping cough caused by B. parapertussis range
from 2 to 36% [15,16]. However, B. parapertussis infections are
probably underestimated, most likely because the disease is milder
than that caused by B. pertussis [17,18]. Cross-protection conferred
by existing B. pertussis vaccines, especially aPV, against B.
parapertussis infection is very poor [19]. It has recently been shown
that one of the reasons for this poor cross-protection is the
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allows this organism to escape anti-B. pertussis antibody-mediated
immunity [20].
We have recently constructed BPZE1, a live attenuated B.
pertussis vaccine strain, resulting from the genetic inactivation or
removal of three major virulence factors, tracheal cytotoxin,
pertussis toxin (PTX) and dermonecrotic toxin, as described in
detail in [21]. Athough BPZE1 does not produce tracheal
cytotoxin and dermonecrotic toxin, it still produces immunogenic
PTX, albeit in a genetically detoxified form. This vaccine strain is
highly protective against B. pertussis challenge in mouse models and
showed genetic stability during in vivo or in vitro passages [22].
Interestingly, BPZE1 also conferred significant cross-protection
against B. parapertussis infection [21]. In this study, we investigated
the mechanisms underlying the protective immunity induced by
BPZE1 against B. pertussis and B. parapertussis by using adoptive
transfer to severe combined immunodeficiency (SCID) mice.
Results
B. pertussis causes persistent infection in SCID mice
In immuno-competent mice, infection with 10
5 to 10
6 virulent
B. pertussis results in a typical increase of the bacterial burden by a
factor of 10 during the first 7 days, followed by a general decline
with a total clearance of the bacteria at day 30 after infection
[21,23]. Extra-pulmonary disseminated B. pertussis infection is
rarely seen, both in mice [24] and in humans [25]. This
colonisation profile shows control of the bacteria resulting
probably from a combination of both innate and adaptive immune
responses [23].
Immuno-compromised mice, deficient in B and/or T cell
responses fail to clear B. pertussis infection [26–29] and may
therefore constitute good in-vivo models to address the effector
mechanisms of adaptive immunity to B. pertussis infection. In order
to investigate the role of the BPZE1-induced adaptive immune
responses in the clearance of B. pertussis, we therefore used SCID
mice defective in T, B and natural killer (NK) cell populations.
First, the mice were intranasally (i.n.) infected with B. pertussis
BPSM [30], and the numbers of viable bacteria recovered from
the lungs were determined at different time points. As shown in
Fig. 1, three hours (Day 0) and eight weeks (Day 60) after infection,
B. pertussis BPSM organisms were present in the lungs of the SCID
mice. Whereas all the bacteria were essentially cleared in the
immuno-competent mice 8 weeks after challenge, the SCID mice
contained roughly 10 fold more bacteria at 8 weeks after challenge
compared to day 0, similar to what is usually seen in immuno-
competent mice at day 7 post-infection [21,22]. These results are
consistent with the fact that adaptive immunity is required for the
clearance of B. pertussis from the mouse respiratory tract [23], and
allow us to use SCID mice as a suitable model to identify the
effector mechanisms of adaptive immunity induced by BPZE1
against B. pertussis.
Adoptive transfer of spleen cells or serum from BPZE1-
vaccinated mice protects SCID mice against B. pertussis
SCID mice were thus used to study the contribution of T cells
and antibodies in the protection conferred by BPZE1 against B.
pertussis using transfer experiments. Either serum (100 ml) or whole
spleen cells (50610
6) from non-immunized or mice immunized
with BPZE1 eight weeks previously were transferred to groups of
five female SCID mice. Prior to transfer we verified that the
BPZE1-vaccinated mice had produced B. pertussis-specific T and B
cells (data not shown). This was done by using B. pertussis antigen-
specific T cell proliferation assays and by measuring anti-B. pertussis
antibodies in the serum, as described [21]. 24 hours after transfer,
the SCID mice were i.n. infected with 10
6 B. pertussis BPSM and
sacrificed 7 days later to determine the numbers of colony-forming
units (CFU) in the lungs. As shown in Fig. 2a, transfer of 100 ml
serum from BPZE1-immunized BALB/c mice conferred strong
protection, as no bacteria were detected in the lungs within 7 days
after challenge. No protection was achieved with serum transfer
from non-immunized mice, as at day 7 post infection, the bacterial
burden (,10
7) was similar to that observed in the infected control
mice. In addition to the serum, the transfer of spleen cells from
BPZE1-immunized mice also conferred a significant level of
protection to SCID mice against infection with B. pertussis,a s
evidenced by a reduction by approximately 2 logs in CFU
compared to non-transferred mice or to SCID mice that had
received spleen cells from non-vaccinated donors (Fig. 2b). In a
parallel experiment, the levels of protection increased with
increasing amounts of T cells transferred (Fig. 2c). These data
thus demonstrate that both B and T cells are involved in BPZE1-
mediated protection.
Role of CD4
+ and CD8
+ T cells in BPZE1-mediated
immunity
We have previously shown that BPZE1 vaccination induces
both B. pertussis-specific antibodies and IFN-c, whereas it induces
only low levels of Th2 cytokines [21]. Several studies have pointed
to an important role of IFN-c in the control against B. pertussis
infection [24,27,29]. Since IFN-c can be produced by different cell
types, we wanted to know whether either the CD4
+ or the CD8
+ T
cells are responsible for B. pertussis-specific IFN-c production upon
vaccination with BPZE1. The splenocytes of non-immunized and
of BPZE1-immunized mice were isolated 8 weeks after vaccination
and stimulated in vitro with PTX (10 mg/ml) or filamentous
hemagglutinin (FHA, 5 mg/ml) for 24 hours. Their surface
expression of CD4 and CD8 (Fig. 3a), as well as their intracellular
IFN-c production were then analyzed by flow cytometry. As
shown in Fig. 3b, most of the PTX-specific IFN-c was produced by
the CD4
+ or the CD4
2/CD8
2 T cells from BPZE1-immunized
mice, whereas the CD8
+ T cells did not contribute to the PTX-
specific IFN-c response at a significant level (Fig. 3c). In fact, most
of the IFN-c was produced by the CD4
2/CD8
2 T cells, most
likely NK or NKT cells. As expected, neither CD4
+ nor CD8
+,
Figure 1. B. pertussis causes persistent respiratory infection in
SCID mice. Two groups (BALB/c, white columns; and SCID, black
columns) of 5 mice were infected i.n. with ,1610
6 B. pertussis BPSM
and sacrificed 3 h (Day 0) or eight weeks later (Day 60) for CFU counts in
the lungs. The results are expressed as means of log CFU values per
lung (6 standard error) and are representative of three independent
experiments.
doi:10.1371/journal.pone.0010178.g001
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2/CD8
2 T cells from non-vaccinated mice produced
PTX-specific IFN-c. Similar results were obtained when FHA was
used (data not shown).
More recently, IL-17-producing Th17 cells have been proposed
to participate in protective cellular immunity against B. pertussis
[31], and PTX promotes the generation of IL-17- producing
CD4
+ T cells [32]. On the other hand, FHA, present on the
surface of BPZE1 [21], has been shown to induce the production
of IL-10 [33], a cytokine produced by type 1 regulatory T (Treg)
cells and serving to evade the protective Th1 responses. Since it
was not known whether administration of BPZE1 induces IL-17 or
IL-10 in vivo, we stimulated spleen cells from BPZE1-vaccinated
mice and from naı ¨ve control mice with FHA and measured the
production of these two cytokines in the culture supernatants.
High amounts of both IL-10 and IL-17 were produced upon FHA
stimulation by spleen cells from BPZE1-vaccinated and naı ¨ve
mice. The addition anti-IL-10 antibodies significantly decreased
IL-17 secretion, suggesting a positive contribution of IL-10 on IL-
17 production (Fig. 4a). In contrast to IL-17, the FHA-induced IL-
10 production was much higher in the spleen cells from BPZE1-
immunized mice than from the control animals. Blocking IL-17 by
using anti-IL-17 antibodies completely abrogated IL-10 secretion
(Fig. 4b). These data show that IL-10 is an essential factor for IL-
17 production and reciprocally, and suggest a collateral develop-
ment pathway between IL-17-producing Th17 cells and IL-10-
producing Treg cells.
We next examined in vitro the effects of blocking anti-IL-10 and
anti-IL-17 on the proliferation and other cytokines produced by
FHA-stimulated spleen cells. Incubation of whole spleen cells from
BPZE1-immunized mice with FHA induced stronger proliferation
and higher IFN-c and IL-2 amounts than those from naive
littermates (Fig. 4c–e). The addition of blocking anti-IL-10
antibodies to the culture slightly increased proliferation, had no
effect on the IFN-c production, but increased IL-2 production in
the BPZE1-immunized group (Fig. 4c–e). When anti-IL-17
antibodies were added to the culture, proliferation was slightly
inhibited (Fig. 4c), whereas the IFN-c production strongly
inhibited (Fig. 4d), and the IL-2 production was augmented
(Fig. 4e). Thus, proliferation appeared to be inversely regulated by
IL-10 and IL-17.
Since BPZE1 administration resulted in the production of both
Th1 and Th17 CD4
+ T cell-mediated B. pertussis-specific IFN-c and
IL-17, respectively, we investigated whether it is the BPZE1-
induced CD4
+ T cell population that confers protection in the
SCID mouse model. As shown in Fig. 5 (left panel), BPZE1
immunization induced PTX-specific CD4
+ IL-17-producing T
cells. Importantly, the IL-17-producing T cells were different from
the IFN-c-producing cells (Fig. 5, right panel), and we did not
observe IFN-c-, IL-17- double positive CD4
+ T cells. CD4
+ and
CD8
+ T cells were thus purified from BPZE1-immunized mice
(Fig. 6a) using a cell sorter separation technology, as described in
Materials and Methods, and then transferred to SCID mice 24 h
prior to B. pertussis BPSM challenge. As illustrated in Fig. 6b,
7.5610
5 purified CD4
+ T cells from BPZE1-immunized mice
transferred to SCID mice provided significant protection against B.
pertussis challenge, whereas the transfer of the same amount of CD8
+
T cells did not. Thus, both the in vitro and the in vivo results indicate
that within the T cell compartment, the CD4
+ T cells play a major
Figure 2. Transfer of protection by spleen cells and serum from BPZE1-immunized mice. 100 ml of serum (a)o r5 0 610
6 whole spleen cells
(WSC) (b) or indicated amounts of WSC (c) from non-immunized (Naı ¨ve) or BPZE1-immunized (BPZE1) BALB/c mice were transferred intraperitoneally
to SCID mice 24 h before they were intranasally infected with virulent B. pertussis BPSM (1610
6 CFU). Non-transferred SCID mice (No transfer) served
as controls. The mice were sacrificed 7 days after challenge, and CFUs in the lungs were counted. The results are expressed as means of log CFU
values per lung from 5 mice per group (6 standard error) and are representative of three independent experiments.
doi:10.1371/journal.pone.0010178.g002
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through their ability to secrete antigen specific IFN-c and IL-17.
BPZE1-induced cellular but not humoral immunity cross-
protects against B. parapertussis
Although wcPV provides some level of protection against B.
parapertussis infections in mouse models, aPV does not, but instead
enhances colonisation by B. parapertussis [19]. In contrast, we have
previously shown that administration of BPZE1 protects mice
against B. parapertussis [21]. To identify the BPZE1-induced
immune effector functions that provide cross-protection against
B. parapertussis, we transferred antisera or spleen cells from BPZE1-
immunized mice to SCID mice prior to B. parapertussis challenge.
First, we confirmed that BPZE1 provides cross-protection against
B. parapertussis. As shown in Fig. 7a, BPZE1-immunized mice or
animals infected with B. parapertussis 8 weeks prior to re-infection
showed substantially reduced CFU counts in the lungs, in
comparison to non-immunized but challenged control mice.
Groups of five SCID mice were then injected with either 100 ml
of serum or 50610
6 whole spleen cells from non-immunized,
BPZE1-immunized or B. parapertussis-infected BALB/c mice 8
weeks previously. One day later the SCID mice were challenged
with B. parapertussis and sacrificed 7 days post-challenge to
determine bacterial counts in the lungs. The transfer of serum
from non-immunized or BPZE1-immunized BALB/c mice had no
significant effect on colonization by B. parapertussis during the first 7
days post-challenge (Fig. 7b), whereas, transferring B. parapertussis
immune serum to recipient SCID mice resulted in total clearance
of the bacteria from the lungs at day 7. Unlike the serum, transfer
of spleen cells from BPZE1-immunized mice resulted in significant
protection of the SCID mice against B. parapertussis infection,
although slightly lower than that obtained by the transfer of spleen
cells from B. parapertussis-infected mice (Fig. 7c). BPZE1-induced
cross-protection against B. parapertussis is thus essentially T-cell
mediated, while immunity induced by B. parapertussis infection
elicits both protective B and T cells responses.
Serum from BPZE1-vaccinated mice is able to kill B.
pertussis but not B. parapertussis
The failure of serum from BPZE1-immunized mice to protect
SCID mice against B. parapertussis infection suggests that it is
unable to kill B. parapertussis bacteria. We thus carried out a serum
killing assay to compare survival of B. parapertussis with that of B.
pertussis after incubation with serum from naı ¨ve or BPZE1-
immunized mice. 300 CFU of B. pertussis or B. parapertussis were
incubated with serum from naı ¨ve or BPZE1-immunized mice for
1 h at 37uC. The bacteria were then plated on BG-blood agar for
CFU counting. Significant B. pertussis killing was observed by
serum from BPZE1-immunized mice compared to serum from
non-immunized mice (Fig. 8a), whereas the BPZE1 serum did not
Figure 3. CD4
+ T phenotype of IFN-c-producing T cells following BPZE1 administration. BALB/c mice were left untreated (Naı ¨ve) or
immunized intranasally with 10
6 CFU of B. pertussis BPZE1 (BPZE1). Eight weeks later, the mice were sacrificed and spleens of three individual mice per
group were pooled and homogenized to obtain single-cell suspensions. 2.5610
6 cells were cultured in triplicate overnight in the presence of 10 mg/
ml PTX (PTX) or left unstimulated (Medium). Spleen-derived T cells were then labelled for surface expression of CD4 and CD8 (a), and intracellular IFN-
c expression by CD4
+ (b) and CD8
+ (c) T cells was assessed by flow cytometry. The results shown are representative of three independent
experiments.
doi:10.1371/journal.pone.0010178.g003
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compared to serum from non-immunized mice (Fig. 8b), indicat-
ing that the serum from BPZE1-immunized mice has no
antimicrobial activity against B. parapertussis although it is active
against B. pertussis.
Discussion
In this study, we used SCID mice, deficient in B, T and NK T
cells, to examine the mechanisms of protective immunity against
B. pertussis and B. parapertussis i.n. infections induced by the recently
developed live attenuated vaccine strain BPZE1. Although the
mouse model has its obvious limitations, it is the most widely used
animal model to study pertussis vaccines, and there has been a
good correspondence between vaccines that protect children
against pertussis and those that protect mice against i.n. infection
with B. pertussis [34]. We found that, unlike immuno-competent
mice, SCID mice are unable to clear B. pertussis infection, thus
qualifying them as a suitable animal model to study the
contribution of the different effectors molecules and cells in the
protective adaptive immunity against Bordetella. Previous studies
using gene knock-out mice with deficiencies for specific immune
functions, including Th1-type cytokines and immunoglobulins,
have already shown the importance of both B cells and CD4
+ T
cells in immunity against B. pertussis [23,26–29,34]. As a
complement to these studies, transfer experiments to immuno-
deficient mice, such as SCID mice, enable us to identify molecules
and cell types that exert direct effectors functions against the
invading pathogen. We therefore used that technology to identify
the effectors molecules or cells involved in BPZE1-induced
protection. In this model, both serum-free T cells and anti-BPZE1
antisera were able to provide significant protection against B.
pertussis infection, indicating that both antibodies and T cells
contribute to BPZE1-induced protection and that either one can
confer protection. The mechanisms of immunity induced by
BPZE1 are thus comparable to that induced by infection with
virulent B. pertussis.
Although we have so far tested only one B. pertussis challenge
strain and other, in particular recent, circulating clinical isolates
need to be tested in future studies, it is likely that BPZE1 protects
against a variety of B. pertussis strains, since nasal immunization
with BPZE1 even protects against B. parapertussis infection [21].
The ability of pertussis vaccines to protect against B. parapertussis
has remained controversial. Several epidemiological and animal
Figure 4. Cytokine production profile of splenocytes from BPZE1-immunized mice. BALB/c mice were left untreated (Naı ¨ve) or immunized
intranasally with 10
6 CFU of B. pertussis BPZE1 (BPZE1). Eight weeks later, the mice were sacrificed, and spleen cells were stimulated in triplicate in the
presence (black bars) or absence (white bars) of 10 mg/ml FHA, with or without (Medium) 10 mg/ml anti-IL-10 or anti-IL-17 antibodies. After 60 h of
culture, the secretion of IL-17 (a), IL-10 (b), IFN-c (d) and IL-2 (e) in the culture supernatants was determined by sandwich ELISA, and the proliferation
was assessed by [
3H] thymidine incorporation (c). The results are the expressed as mean values (6 standard error) for triplicate cultures from four
mice per group and are representative of three experiments.
doi:10.1371/journal.pone.0010178.g004
Novel Live Pertussis Vaccine
PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10178vaccine studies have shown poor cross-protection of B. pertussis
vaccines against B. parapertussis, especially when aPV are used
[15,19]. However, infection with B. pertussis has been reported to
protect mice against B. parapertussis infection, and vice versa
[35,36]. Since nasal vaccination with BPZE1 mimics much closer
B. pertussis infection than systemic immunization with aPV, the
cross-protective results observed upon BPZE1 administration are
consistent with the previously observed reciprocal immunity
induced by infection [36].
Interestingly, only the transfer of T cells from BPZE1-
immunized mice to SCID mice provided protection against B.
parapertussis infection, indicating that the BPZE1-induced cross-
protection is cell-mediated. However, this does not rule out that
other effector mechanisms may also contribute to protection
against B. parapertussis. In contrast, BPZE1-induced antibodies did
not protect against B. parapertussis infection. This was confirmed by
the fact that BPZE1-induced antibodies were not able to kill B.
parapertussis, whereas they were efficient in killing B. pertussis. These
findings are consistent with recent reports showing that, although
anti-B. pertussis antibodies cross-react with B. parapertussis antigens,
B. parapertussis displays an O antigen that is not produced by B.
pertussis, and that inhibits binding of the antibodies to the bacterial
cell surface [20] and protects the bacteria from complement-
mediated killing by inhibiting complement C3 deposition on the
bacterial surface [37]. The presence of O antigen on the surface of
B. parapertussis may thus explain why BPZE1-induced cross-
protection is solely T-cell mediated. Unlike protection resulting
from infection [38], aPV-induced protection against pertussis is
essentially antibody mediated [34]. It is therefore not surprising
that vaccination with aPV offers little protection against B.
parapertussis.
Considering the importance of T cell-mediated immunity in the
protection against B. pertussis and B. parapertussis, we analyzed the
BPZE1-induced T cell responses in more detail. Previous studies
had already shown that vaccination with BPZE1 induces a strong
Th1 response in mice, as evidenced by high levels of antigen-
specific IFN-c and low IL-5 responses [21]. BPZE1-induced
antigen-specific IFN-c was confirmed here, and we further show
that BPZE1 also induces antigen-specific IL-17. This cytokine has
previously been shown to be associated with protection against B.
pertussis via activation of B. pertussis killing by macrophages, and to
act in concert with IFN-c although probably through distinct
Figure 5. IFN-c and IL-17 are produced by distinct B. pertussis-specific CD4
+ T cell subsets from BPZE1-immunized mice. BALB/c mice
were left untreated (Naı ¨ve) or immunized intranasally with 10
6 CFU of B. pertussis BPZE1 (BPZE1). Eight weeks later, the mice were sacrificed, and
spleens of three individual mice per group were pooled and homogenized to obtain single-cell suspensions. 2.5610
6 cells were cultured in triplicate
overnight in the presence (PTX) or absence (Medium) of 10 mg/ml PTX. Spleen-derived T cells were then labelled for surface expression of CD4, and
intracellular IFN-c and IL-17 expression was assessed by flow cytometry. The results are representative of three independent experiments.
doi:10.1371/journal.pone.0010178.g005
Figure 6. Protection by purified CD4
+ T cells from BPZE1-
immunized mice. Purified CD4
+ or CD8
+ T cells from BPZE1-
immunized BALB/c mice (a) were transferred intraperitoneally to naı ¨ve
SCID mice 24 h before they were intranasally infected with virulent B.
pertussis BPSM. The mice were sacrificed 8 days later, and CFUs present
in the lungs were counted (b). The results are expressed as means of
log CFU values per lung from 5 mice per group (6 standard error) and
are representative of two independent experiments.
doi:10.1371/journal.pone.0010178.g006
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PLoS ONE | www.plosone.org 6 April 2010 | Volume 5 | Issue 4 | e10178Figure 7. BPZE1-induced immunity cross-protects against Bordetella parapertussis. BALB/c mice were intranasally infected with 1610
6 CFU
of B. pertussis BPZE1 (BPZE1) or B. parapertussis (Bpp) or left untreated (Naı ¨ve). The mice were then challenged 8 weeks later with 1610
6 CFU B.
parapertussis and sacrificed 7 days after challenge for counting of CFUs in the lungs (a). 100 ml of sera (b)o r5 0 610
6 whole spleen cells (c) from
BPZE1-immunized, B. parapertussis-infected or naı ¨ve mice were injected intraperitoneally into naive SCID mice. 24 h later, the mice were intranasally
infected with B. parapertussis and sacrificed seven days later for CFU counts in the lungs. The results are expressed as means of log CFU values per
lung from 5 mice per group (6 standard error) and are representative of three independent experiments.
doi:10.1371/journal.pone.0010178.g007
Figure 8. Survival of B. pertussis and B. parapertussis in the presence of serum from non-immune or BPZE1-immunized mice. 300 CFU
of B. pertussis (a) and B. parapertussis (b) were incubated at 37uC for 1 h in the presence of 100 ml of 80% serum from unimmunized (Naı ¨ve) or BPZE1-
immunized (BPZE1) mice and then plated onto Bordet Gengou blood agar plates for CFU counting. The results are presented as percent survival
relative to that of a PBS control (in the absence of serum) (6 standard error) for 3 mice per group, evaluated on 3 different plates per mouse, and are
representative of three independent experiments.
doi:10.1371/journal.pone.0010178.g008
Novel Live Pertussis Vaccine
PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10178mechanisms [32]. Both IFN-c and IL-17 were produced by B.
pertussis antigen-specific CD4
+ T cells in BPZE1-immunized mice,
although, and as expected, by two different CD4
+ T cell sets,
indicating that in addition to antibodies, BPZE1 vaccination also
induces Th1 and Th17 cells. We did not find CD4
+ IL17
+ IFNc
+
T-cell in our model. Lack of double positive has also been reported
in other studies on mice [39,40] and humans [41,42], although
human CD4
+ T cells have been shown to be able to secrete both
IL-17 and IFN-c under some circumstances [43,44]. We also
detected significant amounts of IL-17 and IFN-c secretion by FHA
stimulated-spleen cells from naı ¨ve mice, although the cytokine
amounts were higher in the BPZE1-vaccinated mice than in the
naı ¨ve animals. It has been shown by Higgins et al. [31] that FHA-
stimulated spleen cells from mice vaccinated with pertussis
vaccines produce IL-17 and IFN-c, while naı ¨ve mice do not.
These discrepancies may be due to the differences in the amounts
of FHA used to stimulated the spleen cells (10 mg/ml used here,
compared to 2 mg/ml used by [31]). Transfer of purified CD4
+ T
cells comprising both the Th1 and the Th17 subsets, but not of
CD8
+ T cells protected the SCID mice against B. pertussis
infection.
In addition to Th1-type cytokines and IL-17, BPZE1 vaccina-
tion also induced IL-10, an anti-inflammatory and regulatory
cytokine, previously reported to down-modulate Th-1 type
responses and to help B. pertussis to evade protective immunity
[33]. We found that neutralizing IL-10 by blocking antibodies
indeed increased T cell proliferation in naı ¨ve and vaccinated mice,
and IL-2 secretion in vaccinated mice upon stimulation with FHA
in vitro, but inhibited IL-17 secretion in both groups. These
observations are in disagreement with reports on human T cells,
which have demonstrated that neutralization of IL-10 or TGF-b
abrogated IL-17 production, while it increased IFN-c production
by PBMC from Hepatitis C virus-infected patients [44]. However,
although the mechanism of this IL-10-dependent induction of IL-
17 remains to be investigated, our observation is consistent with
previous report [42] and with the results of a very recent study
indicating that enzymatically inactive PTX induces IL-10
production by human monocyte-derived dendritic cells, which in
turn enhances IL-17 production [45]. However, it has been
proposed that the IL-10 effect on IL-17 production is indirect via
its ability to fine tune regulatory cytokine expression. In addition to
PTX, the B. pertussis lipopolysaccharide may also contribute to the
induction of IL-10 and subsequently IL-17 [46]. The major
triggering molecule may perhaps be identified through the use of
defined B. pertussis mutants lacking the genes that code for PTX.
The fact that neutralization of IL-10 had a much stronger effect on
the reduction of IL-17 production than on the IFN-c secretion
supports the notion that both cytokines are produced by distinct T
cell subtypes during B. pertussis infection [47].
Conversely, neutralizing IL-17 with blocking antibodies reduced
IL-10 secretion in vaccinated mice and IFN-c production both in
naı ¨ve and in vaccinated mice, but increased IL-2 secretion in
vaccinated mice. These findings suggest that IL-17 is an important
cytokine not only for the induction of IFN-c-producing Th1 cells,
but also for IL-10 secretion after BPZE1 administration. The fact
that blocking IL-17 increased IL-2 secretion, while decreasing IL-
10 secretion, leads us hypothesize that IL-17 blocking did not act
directly on IL-2 secretion, but perhaps indirectly via the inhibition
of IL-10 secretion, known to be an inhibitor of IL-2 production.
However we cannot exclude a direct blocking IL-17 effect on the
increased IL-2 secretion. In naı ¨ve mice, neutralizing IL-10 or IL-
10 and IL-17 did not affect IFN-c and IL-2 secretion, respectively.
Thus, it appears that even in naı ¨ve mice, IL-10 and IL-17
differentially modulated cytokine secretion.
Collectively, the data presented here show that a single nasal
administration of the live attenuated B. pertussis BPZE1 vaccine
strain is able to induce the broad spectrum of protective effector
mechanisms associated with control of infection by human
adapted B. pertussis species. Both B and CD4
+ T cells contribute
into BPZE1-induced protection against B. pertussis, while cross-
protection against B. parapertussis in essentially T cells mediated.
The BPZE1-induced T cells comprise the IFN-c-producing Th1-
type and Th17 cells, both likely to participate in the cell-mediated
protection. The involvement of Th17 in the protective immunity
against pertussis has only been very recently recognized, but may
be particularly relevant in the light of the growing evidence that
these cells play an important role in mucosal immunity, especially
towards respiratory pathogens [48]. Since B. pertussis is a strictly
respiratory pathogen, there is little doubt that future studies will
clarify the role of Th17 cells in the protective mechanisms at the
mucosal site that constitutes the port of entry of this important
pathogen. In addition, the role of the B. pertussis-specific IFN-c
producing CD4
2/CD8
2 cells from BPZE1-immunized mice
warrants further investigation. These cells are most likely NK or
NKT cells. It has previously been demonstrated that B. pertussis
infection induces high frequencies of IFN-c-secreting NK cells and
that these cells play an important role in protection, especially
against disseminated B. pertussis infection [27]. In future studies we
will thus address whether the BPZE1-induced IFN-c-producing
CD4
2/CD8
2 cells are NK cells that also may participate in
protection against B. pertussis and B. parapertussis infection.
Materials and Methods
Ethics statement
All animal experiments were performed following the guidelines
of the Institut Pasteur de Lille animal study board, which conforms
to the Amsterdam Protocol on animal protection and welfare, and
Directive 86/609/EEC on the Protection of Animals Used for
Experimental and Other Scientific Purposes, updated in the
Council of Europe’s Appendix A (http://conventions.coe.int/
Treaty/EN/Treaties/PDF/123-Arev.pdf). The animal work also
complied with the French law (nu 87-848 dated 19-10-1987) and
the European Communities Amendment of Cruelty to Animals
Act 1976. All manipulations involving animals were carried out by
qualified personnel. The animal house was placed under the direct
control of the Institut Pasteur de Lille director who is the
‘‘designated responsible person’’ under French law. The study has
been approved by Ethical Committee for experiments on animals
of the region Nord-Pas-de-Calais (approval number AF 03/2009).
Bordetella strains and growth conditions
The B. pertussis strains used in this study were streptomycin-
resistant BPSM [30] and BPZE1 [21], both derived from B.
pertussis Tohama I. The B. parapertussis strain was a streptomycin-
derivative of strain 12822, kindly provided by N. Guiso, Institut
Pasteur de Paris. All Bordetella strains were grown on Bordet-
Gengou (BG) agar (Difco Laboratories, Detroit, Michigan, United
States) supplemented with 1% glycerol, 20% defibrinated sheep
blood, and 100 mg/ml streptomycin at 37uC. After growth, the
bacteria were harvested by scraping the plates and resuspended in
phosphate-buffered saline (PBS) at the desired density.
Animals, immunization and infection protocol
Three to four weeks-old female BALB/c and SCID mice were
obtained from Charles River (l’Abresle, France) and maintained
under specific pathogen-free conditions in the animal facilities.
The mice were i.n. immunized as previously described [21,22].
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pentobarbital (CEVA Sante ´ Animale - La Ballastie `re, France) and
inoculated by pipetting 20 ml PBS containing approximately
1610
6 CFU of B. pertussis BPZE1, B. pertussis BPSM or B.
parapertussis onto the tip of the nares. The mice were sacrificed 7
days after challenge, and their lungs were harvested, homogenized
in PBS and plated in serial dilutions onto BG-blood agar to count
CFUs after incubation at 37uC for three to four days, as described
[21,22].
Intracellular staining
For the analysis of intracellular IL-17 and IFN-c, 2.5610
6 cells/
ml from naı ¨ve or mice immunized 8 weeks previously with BPZE1
were cultured in 48-well tissue culture plates (Nunclon, Roskilde,
Denmark) in the presence of 10 mg/ml of heat-inactivated PTX or
FHA for 18 to 20 h. PTX was purified from FHA-deficient B.
pertussis BPGR4 [49] and FHA from PTX-deficient BPRA [50] as
described in [51] and [52], respectively. Brefeldin A (One mlo fB D
GolgiPlug, BD Biosciences) was added to the cultures for the last
5 h to prevent secretion of intracellular cytokines. One million
cells were labelled with the FITC-conjugated anti-CD4 antibody
(clone H129.19; BD Biosciences) and APC-conjugated anti-CD8
antibody (clone 53-6.7; BD Biosciences) for 30 min at 4uC. Cells
were then washed and fixed with BD Cytofix/Cytoperm
TM Plus
Fixation/Permeabilisation Kit, according to the manufacturer’s
protocol (BD Biosciences). To label intracellular IL-17 or IFN-c,
cells were incubated with phycoerythrin-conjugated anti-IL-17
(clone TC11-18H10) or anti-IFN-c antibodies (clone XMG1.2;
BD Biosciences) in the presence of saponin for 30 min at 4uC,
washed, and acquired on a cytofluorometer (Becton Dickinson).
Lymphocytes were gated by their forward and side light-scattering
properties, and 100,000 cells were acquired. Analysis was done
with the Cell Quest program.
In vitro studies
For in vitro proliferation assays, whole spleen cells (16106) were
seeded in U-shaped 96-well culture plates in a final volume of
200 ml RPMI 1640 with 10% FBS (Invitrogen, Carlsbad,
California) containing 2 mM glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin, 10 mM HEPES, 1 mM sodium pyru-
vate and 50 mM 2-ME, and stimulated for 60 h with FHA (10 mg/
ml). Proliferation was assessed by the incorporation of 3[H]TdR
during the last 16 h of culture. Results are expressed as mean
counts per minute of 3[H]TdR incorporation for triplicate cultures
of groups with three to four mice. Culture supernatants were taken
after 48 h of stimulation with FHA, and their concentrations of
IFN-c, IL-2, IL-10 and IL-17 were determined by ELISA (R&D
systems, Abingdon, U.K.) using manufacturer’s specifications. In
some experiments, the medium was supplemented with 10 mg/ml
blocking anti-IL-10 (clone JES5-2A5; BD Biosciences) or anti-IL-
17 (clone TC11-18H10; BD Biosciences) antibodies.
Cell separation
To enrich for CD4+ and CD8+ T cells, spleen cells were
incubated with FITC-conjugated anti-CD4 antibodies (BD
Biosciences) or PE-conjugated anti-CD8 antibodies (BD Biosci-
ences), for 30 min at 4uC. After washing, cells were resuspended,
and CD4+ or CD8+ T cells were isolated using a cell sorter
separation technology (Beckman coulter). The CD4+ and CD8+
cell populations were sorted to a purity of .98% and .99%,
respectively.
Adoptive transfer
To study protection after passive/adoptive transfer, serum
(100 ml), whole spleen cells (20 - 50610
6) or purified CD4
+ or
CD8
+ (7.5610
5) spleen T cells from non-immunized mice or mice
immunized with BPZE1 eight weeks previously were injected
intraperitoneally to SCID mice. 24 h later, the mice were infected
with B. pertusssis BPSM or B. parapertussis, and protection was
assessed on day 8 as described above.
Serum-killing assays
Bacteria were grown for 48 h on BG agar and then diluted to
600 CFU/ml in PBS. One microliter was added to 80% mouse
serum diluted in PBS, in a final volume of 200 ml. After one h of
incubation at 37uC, 100 ml was plated onto BG-blood agar and
incubated at 37uC for CFU counting.
Statistical analysis
Results were analysed using the unpaired Student t test and the
ANOVA test (GraphPad Prism program) when appropriate.
Differences were considered significant at p#0.05.
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